What is claimed:

1. An antibody comprising a heavy chain constant (CH) region comprising, from N-terminus to C-terminus, a CH1 domain, a hinge, a CH2 domain, and a CH3 domain wherein:

(a) the CH1 domain comprises a human IgG1 CH1 domain or a human IgG4 CH1 domain having the amino acid sequence DKKV or DKRV from positions 212 to 215 (EU numbering),

(b) the hinge comprises a human IgG1 or a human IgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering) and a human IgG2 lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering),

(c) the CH2 domain comprises a human IgG4 CH2 domain amino acid sequence from positions 237 to 340 (EU numbering), and

(d) the CH3 domain comprises a human IgG1 or a human IgG4 CH3 domain sequence from positions 341 to 447 (EU numbering), and

wherein the antibody is capable of binding to an FcγR with lower affinity than a corresponding antibody comprising a wild-type IgG1 or wild-type IgG4 heavy chain constant region, the antibody is capable of binding FcγRIIA and optionally FcγRIIB, and the antibody is capable of binding FcγRIIA with higher affinity compared to its binding affinity to FcγRIIB.

2. The antibody of claim 1, wherein: (a) the CH1 domain comprises the amino acid sequence DKKV (SEQ ID NO: 4), and the hinge comprises the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8), or (b) the CH1 domain comprises the amino acid sequence DKRV (SEQ ID NO: 5), and the hinge comprises the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).

3. The antibody of claim 1 or 2, wherein the CH2 domain comprises the amino acid sequence SEQ ID NO: 10.

4. The antibody of any one of claims 1 to 3, wherein the CH3 domain comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 41, and SEQ ID NO: 42.

5. The antibody of claim 1, wherein the CH region has an amino acid sequence identical to SEQ ID NO: 1 or SEQ ID NO: 2.

6. The antibody of claim 1, wherein the CH region has an amino acid sequence identical to SEQ ID NO: 30.

7. The antibody of claim 1, wherein the CH region has an amino acid sequence identical to SEQ ID NO: 31.

8. The antibody of claim 1, wherein the CH region has an amino acid sequence identical to SEQ ID NO: 37.

9. The antibody of claim 1, wherein the CH region has an amino acid sequence identical to SEQ ID NO: 38.

10. The antibody of any one of claims 1 to 9, wherein the antibody exhibits less than 20% CDC cytotoxicity and/or ADCC cytotoxicity, or less than 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable CDC and/or ADCC cytotoxicity, at an antibody concentration of at least 10 nM.

11. The antibody of claim 10, wherein the CDC and/or ADCC cytotoxic activity is at least 5-fold less, or at least 10-fold less than the CDC and/or ADCC cytotoxic activity of a corresponding antibody comprising a wild-type IgG1 or wild-type IgG4 CH region.

12. The antibody of any one of claims 1 to 11 that is a monospecific antibody.

13. The antibody of any one of claims 1 to 11 that is a bispecific antibody.

14. Nucleic acid molecules encoding an antibody of any one of claims 1 to 13.

15. A vector comprising the nucleic acid molecules of claim 14.

16. The vector of claim 15, wherein:

(a) the nucleic acid molecules are operatively linked to an expression control sequence suitable for expression in a host cell, optionally wherein the expression control sequence comprises (i) a promoter selected from the group consisting of SV40, CMV, CMV-IE,

CMV-MIE, UbC, RSV, SL3-3, MMTV, Ubi and HIV LTR, (ii) an expression cassette selected from the group consisting of TetR-ER_{LBD}T2 fusion gene driven by the CMV-MIE promoter, blasticidin resistance gene driven by the SV40 promoter, and Arc-ER_{LBD}T2 fusion gene driven by the CMV-MIE promoter; or (iii) a CMV-MIE/TetO or CMV-MIE/Arc hybrid promoter; and/or

(b) the vector of comprises one or more selectable marker genes selected from the group consisting of bla, bls, BSD, bsr, Sh ble, hpt, tetR, tetM, npt, kanR and pac.

17. A cell comprising the nucleic acid molecules of claim 14.

18. The cell of claim 17, wherein:

(a) the cell comprises a vector of claim 15 or 16; and/or

(b) the nucleic acid molecules are integrated into the genome of the cell; and/or

(c) the cell comprises a nucleic acid encoding a protein expression enhancer and/or

(d) the cell comprises a nucleic acid encoding an XBP polypeptide; and/or

(e) the cell is a eukaryotic cell, an animal cell, a mammalian cell, a CHO cell or a CHO-K1 cell.